within Pharmacolibrary.Drugs.ATC.R;

model R03AL10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.7111111111111112e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,
    adminCount     = 1,
    Vd             = 0.032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.023,
    k12             = 6.944444444444445e-07,
    k21             = 6.944444444444445e-07
    
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>FormoterolAndTiotropiumBromide</td></tr><tr><td>ATC code:</td><td>R03AL10</td></tr><td>route:</td><td>inhaled</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>32</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.88</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Formoterol and tiotropium bromide is a fixed-dose combination inhaler containing a long-acting beta2-adrenergic agonist (formoterol) and a long-acting muscarinic antagonist (tiotropium). It is used as a maintenance treatment of chronic obstructive pulmonary disease (COPD) to improve airflow and reduce exacerbations. This combination is approved and used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults with COPD following inhaled administration of fixed-dose combination formoterol and tiotropium bromide. No dedicated population PK model publication for the fixed combination was found; approximate parameters referenced are based on known single-agent PKs and inhaled route estimates.</p><h4>References</h4><ol><li><p>Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. <i>Drugs</i> 75(6) 665â€“673. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0371-4\">10.1007/s40265-015-0371-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25773742/\">https://pubmed.ncbi.nlm.nih.gov/25773742</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end R03AL10;
